Pulmonary hypertension in congenital heart disease.
Over the past 40 years, significant advances have been made in the diagnosis and management of congenital heart defects. Improvements in diagnostic and interventional cardiology, surgical technique, cardiopulmonary bypass and post-operative intensive care have all contributed to a reduction in mortality and morbidity. Despite these advances, pulmonary hypertension caused by congenital heart defects remains a significant problem in the immediate post-operative period, as well as long-term. This article reviews the pathophysiology of pulmonary hypertension due to congenital heart disease and discusses the options available for the management of this condition.
Raja
Shahzad G
SG
Department of Paediatric Cardiac Surgery, Royal Hospital for Sick Children, Glasgow. drrajashahzad@hotmail.com
Basu
Devika
D
D001783:Blood Flow Velocity; D004730:Endothelium, Vascular / Q000503:physiopathology; D045462:Endothelium-Dependent Relaxing Factors / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D009569:Nitric Oxide / Q000627:therapeutic use; D010102:Oxygen Inhalation Therapy; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011652:Pulmonary Circulation; D012307:Risk Factors; D014655:Vascular Resistance; D014690:Venous Pressure
D045462:Endothelium-Dependent Relaxing Factors; D010726:Phosphodiesterase Inhibitors; D011453:Prostaglandins; D009569:Nitric Oxide